Health

Today’s best in health, discover breakthroughs and tips making an impact now.

AI Model Predicts Immunotherapy-Related Pneumonitis Risk from Routine CT Scans Before Treatment

Anthropic and OpenEvidence Bring Free Medical AI to Doctors in 100 Low-Income Countries

New AI Model Combining Ultrasound and Tomosynthesis Achieves 95.5% Specificity in Breast Cancer Triage

AI Hospital Coding Tools Drive $942M Cost Surge as Hospitals and Insurers Fight Bot War

AI Model Predicts Immunotherapy-Related Pneumonitis Risk from Routine CT Scans Before Treatment

Researchers at MD Anderson Cancer Center developed CIPHER, an AI model that analyzes routine chest CT scans to identify lung cancer patients at risk of developing pneumonitis before immunotherapy begins. The foundation model achieved 0.83 AUC accuracy across multiple datasets, outperforming conventional clinical approaches.

2 Sources

Anthropic and OpenEvidence Bring Free Medical AI to Doctors in 100 Low-Income Countries

Anthropic and OpenEvidence announced a collaboration to provide free AI-powered clinical decision support to physicians in approximately 100 low and middle-income countries. The initiative addresses healthcare disparities by giving doctors in regions like Uganda, Haiti, and Mongolia access to peer-reviewed medical research and treatment guidelines through smartphones, even where electricity is unreliable.

4 Sources

New AI Model Combining Ultrasound and Tomosynthesis Achieves 95.5% Specificity in Breast Cancer Triage

AI Hospital Coding Tools Drive $942M Cost Surge as Hospitals and Insurers Fight Bot War

AI Tuberculosis Screening Could Cut Costs by 23% in Rural Philippines Health Units

Enveda Raises $311M Series E to Advance Nature-Derived AI Drugs Into Clinical Trials

Explore Stories by Date

Stay on top of health updates organized by posting date.

Today

AI Tuberculosis Screening Could Cut Costs by 23% in Rural Philippines Health Units

Ateneo de Manila University researchers found AI-assisted chest radiograph interpretation costs Php 877 per person versus Php 1,142 for manual X-ray interpretation in rural health units. The study highlights how AI tuberculosis screening could extend expert-level TB screening to underserved communities where 739,000 Filipinos developed TB in 2024.

2 Sources

Yesterday

AI Model Predicts Immunotherapy-Related Pneumonitis Risk from Routine CT Scans Before Treatment

Researchers at MD Anderson Cancer Center developed CIPHER, an AI model that analyzes routine chest CT scans to identify lung cancer patients at risk of developing pneumonitis before immunotherapy begins. The foundation model achieved 0.83 AUC accuracy across multiple datasets, outperforming conventional clinical approaches.

2 Sources

24 Sept 2026

New AI Model Combining Ultrasound and Tomosynthesis Achieves 95.5% Specificity in Breast Cancer Triage

Researchers at Sun Yat-sen Memorial Hospital developed a parallel-branch deep learning framework that integrates ultrasound and digital breast tomosynthesis for breast cancer screening. The AI model achieved 95.5% specificity and 0.934 AUC in pathology-confirmed validation, showing particular strength in dense breasts and small lesions while reducing false positives.

2 Sources

AI in Healthcare Drives $1 Billion Cost Surge as Hospitals and Insurers Battle Over Medical Billing

Blue Cross Blue Shield Association reports AI tools generated nearly $1 billion in extra costs over two years as hospitals use AI-assisted hospital documentation to identify secondary conditions. The findings reveal a growing bot war between providers using AI hospital coding tools and insurers deploying AI to scrutinize claims, with patients caught in the middle of escalating healthcare costs.

8 Sources

Enveda Raises $311M Series E to Advance Nature-Derived AI Drugs Into Clinical Trials

Biotech startup Enveda closed a $311 million Series E at a $2 billion valuation to advance AI-discovered drug candidates targeting severe skin conditions, weight loss maintenance, and inflammatory diseases. The Boulder-based company has moved three nature-derived compounds into human trials using its PRISM platform.

2 Sources

23 Sept 2026

Anthropic and OpenEvidence Bring Free Medical AI to Doctors in 100 Low-Income Countries

Anthropic and OpenEvidence announced a collaboration to provide free AI-powered clinical decision support to physicians in approximately 100 low and middle-income countries. The initiative addresses healthcare disparities by giving doctors in regions like Uganda, Haiti, and Mongolia access to peer-reviewed medical research and treatment guidelines through smartphones, even where electricity is unreliable.

4 Sources

17 Sept 2026

AI Tool Matches Psychiatrist-Level Accuracy in Mental Health Evaluations

UTHealth Houston researchers developed an AI tool that performs mental health evaluations at nearly the same accuracy as psychiatric teams. The system analyzes video recordings of patients to assess conditions like schizophrenia, bipolar disorder, and obsessive-compulsive disorder across 10 diagnostic criteria, bringing AI-assisted psychiatry closer to clinical deployment.

2 Sources

16 Sept 2026

MIT Develops Patient-Specific AI Model That Achieves Sub-Millimeter Precision in Minimally Invasive Surgeries

MIT researchers unveiled xvr, an AI model that adapts to individual patients in five minutes and matches real-time X-rays with preoperative 3D scans in seconds with sub-millimeter precision. Published in Nature, the system outperformed existing AI methods by an order of magnitude and could make life-saving procedures like emergency stroke interventions more accessible.

2 Sources

Insilico Medicine Unveils AI-Driven Longevity Vaccines to Target Cellular Drivers of Age-Related Diseases

Insilico Medicine announced Longevity Vaccines, a research initiative using AI-driven drug discovery to develop single-dose therapies that eliminate senescent cells. The programmable circular RNA platform targets cellular drivers of age-related diseases, starting with immunosenescence. The company reported $106 million revenue in H1 2026, marking its first profitable half-year.

2 Sources

15 Sept 2026

Evvy Raises $40M to Transform Women's Health Research with Vaginal Microbiome Data

Women's health startup Evvy secured $40 million in Series B funding led by Catalio Capital Management to expand its AI-powered vaginal microbiome testing platform. The company serves over 100,000 patients and is now entering fertility research, aiming to address the critical data gap in precision medicine for women.

2 Sources

Medicare's AI Prior Authorization Pilot Hits Patients With 83-Day Delays and High Denial Rates

Medicare's AI-driven prior authorization pilot program is causing widespread treatment delays and care denials across six states. Records obtained through a FOIA lawsuit reveal one authorization request went unanswered for 83 days, while vendors warned CMS about system readiness issues before launch. Patients face mounting pain as technical failures plague the WISeR model.

3 Sources

14 Sept 2026

AI Tool Achieves 91% Accuracy Predicting Lung Cancer Immunotherapy Outcomes Across Global Study

Two breakthrough studies demonstrate how AI tools are transforming lung cancer treatment decisions. An AI algorithm achieved 91% accuracy in assessing pathologic response to neoadjuvant chemoimmunotherapy in NSCLC patients, while the I3LUNG project's AI models outperformed standard biomarkers in predicting immunotherapy outcomes across 2,396 patients from six international centers.

3 Sources

11 Sept 2026

Tempus AI launches 100,000 whole-genome dataset for AI-driven healthcare research

Tempus AI announced plans to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information. This will be the first de-identified multimodal whole-genome sequencing dataset built around disease populations and patient outcomes, optimized for AI-driven research. The company plans to expand to one million genomes after completing the initial dataset.

3 Sources

07 Sept 2026

AI-Designed Drug Rentosertib Reverses Biological Age by 3-4 Years in Clinical Trial

Insilico Medicine's rentosertib, an AI-generated drug for lung disease, reduced biological age markers by 3-4 years across six proteomic aging clocks in a 42-patient Phase IIa trial. Published in Nature Biotechnology, the study marks the first clinical evaluation of a drug featuring both an AI-discovered target and AI-designed molecule for aging and disease biology.

10 Sources

Indian Startup Dognosis Uses AI to Train Dogs for Cancer Detection with 90% Accuracy

Bengaluru-based startup Dognosis is pioneering AI-assisted cancer detection using trained dogs equipped with sensor-fitted helmets. A study involving more than 1,500 participants across six hospitals reported over 90% accuracy in detecting seven cancer types through breath samples, though oncologists stress the need for larger independent trials before clinical deployment.

4 Sources

Get all updates into your inbox 💌, Stay Up-to-date for Free 🥳

Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Follow topics that matter to you and stay ahead.

Explore

News Categories

Technology Business Policy Startups Health Science Entertainment

Terms Privacy Content Contact Us